MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4

References

• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52–58.
   PubMed Web of Science ®Google Scholar
• Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136:586–591.
   PubMed Web of Science ®Google Scholar
• Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17:719–732.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Haider S, Jagannathan S, et al. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia. 2014;28:732–738.
   PubMed Web of Science ®Google Scholar
• Stamato MA, Juli G, Romeo E, et al. Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget. 2017;8:106527–106537.
   PubMedGoogle Scholar
• Abdi J, Rastgoo N, Li L, et al. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. J Hematol Oncol. 2017;10:169–180.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yan W, Bai Y, et al. Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. Oncol Rep. 2015;33:448–456.
   PubMed Web of Science ®Google Scholar
• Hale AN, Ledbetter DJ, Gawriluk TR, et al. Autophagy: regulation and role in development. Autophagy. 2013;9:951–972.
   PubMed Web of Science ®Google Scholar
• Thorburn A. Autophagy and its effects: making sense of double-edged swords. PLoS Biol. 2014;12:e1001967.
   PubMed Web of Science ®Google Scholar
• Singh SS, Vats S, Chia AY, et al. Dual role of autophagy in hallmarks of cancer. Oncogene. 2018;37:1142–1158.
   PubMed Web of Science ®Google Scholar
• Pengo N, Scolari M, Oliva L, et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013;14:298–305.
   PubMed Web of Science ®Google Scholar
• Pengo N, Cenci S. The role of autophagy in plasma cell ontogenesis. Autophagy. 2013;9:942–944.
   PubMed Web of Science ®Google Scholar
• Lu Y, Gao J, Zhang S, et al. miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). Cell Death Dis. 2018;9:290–299.
   PubMed Web of Science ®Google Scholar
• Lu C, Chen J, Xu HG, et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology. 2014;146:188–199.
   PubMed Web of Science ®Google Scholar
• Fu XT, Shi YH, Zhou J, et al. MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. Cancer Lett. 2018;412:108–117.
   PubMed Web of Science ®Google Scholar
• Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2014;60:590–598.
   PubMed Web of Science ®Google Scholar
• Zhao J, Nie Y, Wang H, et al. MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene. 2016;576:828–833.
   PubMed Web of Science ®Google Scholar
• Liu L, Shen W, Zhu Z, et al. Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis. Biochem Biophys Res Commun. 2018;498:559–565.
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of coloncancer cells via repression of p21. Mol Biol Cell. 2008;19:4062–4075.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420–5432.
   PubMed Web of Science ®Google Scholar
• Kang ZH, Wang CY, Zhang WL, et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One. 2014;9:e98894.
   PubMed Web of Science ®Google Scholar
• Chauchereau A, Mathieu M, de Saintignon J, et al. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene. 2004;23:8777–8784.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Volinia S, Costinean S, et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci USA. 2012;109:20047–20052.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Suzuki R, Ohguchi H, et al. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015;29:1918–1927.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Huang L, Zhang Z, et al. Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4. Oncol Res. 2017;25:267–275.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Ginnebaugh KR, Yin S, et al. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer. 2015;15:540.
   PubMed Web of Science ®Google Scholar
• Wang H, Li C, Jian Z, et al. TGF-β1 reduces miR-29a expression to promote tumorigenicity and metastasis of cholangiocarcinoma by targeting HDAC4. PLoS One. 2015;10:e0136703.
   PubMed Web of Science ®Google Scholar
• Tanida I, Waguri S. Measurement of autophagy in cells and tissues. Methods Mol Biol. 2010;648:193–214.
   PubMedGoogle Scholar
• Yamamoto A, Tagawa Y, Yoshimori T, et al. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23:33–42.
   PubMed Web of Science ®Google Scholar
• Amodio N, Stamato MA, Gullà AM, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364–1375.
   PubMed Web of Science ®Google Scholar
• Ding H, KL P, Correia C, et al. Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia. 2017;31:1593–1602.
   PubMed Web of Science ®Google Scholar
• Liu YL, Yang PM, Shun CT, et al. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010;6:1057–1065.
   PubMed Web of Science ®Google Scholar
• Gammoh N, Lam D, Puente C, et al. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA. 2012;109:6561–6565.
   PubMed Web of Science ®Google Scholar
• Chiao MT, Cheng WY, Yang YC, et al. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy. 2013;9:1509–1526.
   PubMed Web of Science ®Google Scholar
• Milan E, Fabbri M, Cenci S. Autophagy in plasma cell ontogeny and malignancy. J Clin Immunol. 2016;36:18–24.
   PubMed Web of Science ®Google Scholar
• Lamy L, Ngo VN, Emre NC, et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell. 2013;23:435–449.
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Meng Z, Donohue C, et al. Iron chelators induce autophagic cell death in multiple myeloma cells. Leuk Res. 2014;38:988–996.
   PubMed Web of Science ®Google Scholar
• Cao B, Li J, Zhou X, et al. Clioquinolinduces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway. Sci Rep. 2014;4:5749–5760.
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2004;101(52):18030–18035.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ. 2005;12(Suppl 2):1528–1534.
   PubMed Web of Science ®Google Scholar
• Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, et al. Resistance toproteasome inhibitors and other targeted therapies in myeloma. Br J Haematol. 2018;182:11–28.
   PubMed Web of Science ®Google Scholar
• Chhabra S. Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. Pharmaceuticals (Basel). 2017;10:E40.
   PubMedGoogle Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data usingreal-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• H.J., Ait-mohamed O, Brown EJ, et al. Guidelines for the use and interpretation of assays for monitoRING AUTophagy. Autophagy. 2016;8:445–544.
   Google Scholar
• Yang Q, Wu J, Luo Y, et al. (−)-Guaiol regulates RAD51 stability via autophagy to induce cell apoptosis in non-small cell lung cancer. Oncotarget. 2016;7:62585–62597.
   PubMedGoogle Scholar
• LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth invivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996–5000.
   PubMed Web of Science ®Google Scholar